On April 25, 2026, shares of 10x Genomics fell by 5.4% after mixed first-quarter results from Thermo Fisher Scientific raised concerns about a potential slowdown in the life sciences sector. Although Thermo Fisher’s revenue surpassed expectations at $11.01 billion, its organic growth of 1% fell short of the anticipated 1.4%, leading to investor worries about similar trends affecting 10x Genomics. Despite the current decline, the company’s stock has risen 29% year-to-date but remains 17.8% below its 52-week high of $26.08.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.indexbox.io/blog/10x-genomics-shares-drop-54-on-weak-thermo-fisher-core-growth/
